All In Biotech

Drug Trial Radar · NCT05685602

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

43

Planned (sponsor's estimate)

Start

Jun 12, 2023

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage III Pancreatic Cancer AJCC v8
  • Stage IV Pancreatic Cancer AJCC v8
  • Unresectable Pancreatic Ductal Adenocarcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsies

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo a CT scan

  • EmavusertibBiological

    Given PO

  • Gemcitabine HydrochlorideDrug

    Given IV

  • Nab-paclitaxelDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity rateTime frame: Up to 1 year

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Northwestern University

    Chicago, Illinois

  • Memorial Hospital East

    Shiloh, Illinois

  • University of Kentucky/Markey Cancer Center

    Lexington, Kentucky

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center-South County

    St Louis, Missouri

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri

  • NYU Langone Hospital - Long Island

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

    New York, New York

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

    Madison, Wisconsin

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.